Clene Inc. 8-K

What Happened

• Clene Inc. (and subsidiary Clene Nanomedicine) filed an 8-K on March 17, 2026 disclosing that on March 13, 2026 it entered a Year 3 subaward with New York University (NYU) for up to $8.0 million. The funding is part of a four-year, $45.1 million NIH grant announced Oct. 5, 2023 to support an Expanded Access Program for CNM-Au8 treatment of amyotrophic lateral sclerosis (ALS), awarded under the Accelerating Access to Critical Therapies for ALS Act. The Year 3 Subaward covers the period Sept. 1, 2025 to Aug. 31, 2026.

Key Details

• Year 3 Subaward date: March 13, 2026; 12-month performance period: Sept. 1, 2025–Aug. 31, 2026.
• Amount: up to $8.0 million for Year 3; prior subawards included Year 1 (Columbia) up to $7.3M and Year 2 (amendment with Columbia) up to $8.0M.
• Payment terms: NYU will reimburse Clene based on submitted invoices, no more often than monthly.
• IP and termination: Clene retains background intellectual property (developed at private expense); it will not grant licenses to NYU or the U.S. Government under the subaward. Either party may terminate with 30 days’ written notice. Confidential data will only be delivered if satisfactory safeguards are agreed.

Why It Matters

• This subaward provides reimbursable funding (up to $8.0M) tied to Clene’s CNM-Au8 ALS Expanded Access work, supporting ongoing clinical and program expenses without transferring IP rights.
• Because funds are reimbursed upon invoicing, cash flow timing matters for operations—Clene must incur qualifying costs before being paid.
• The 30-day termination right and the limited IP transfer mean the company keeps control of its technology but also faces some funding risk if the subaward is ended early.